Consolidation With Cema-Cel Shows Favorable Safety in MRD-Positive DLBCL

In an interview with Targeted Oncology, Jeff Sharman, MD, SCRI at Willamette Valley Cancer Institute & Research Center, discusses the safety findings from the phase 2 ALPHA3 study (NCT06500273) and how cemacabtagene ansegedleucel (cema-cel) compares with traditional autologous chimeric antigen receptor (CAR) T-cell therapy when administered in patients with molecular residual disease rather than overt relapsed lymphoma.

Watch the first part of Dr Sharman’s interview.

Early safety data from the ALPHA3 study suggest that cema-cel may have a substantially different tolerability profile when used as consolidation therapy in patients with large B-cell lymphoma who are MRD-positive but have no radiographically detectable disease following frontline chemoimmunotherapy.

Sharman emphasized that this treatment setting differs markedly from the population in which autologous CAR T-cell therapies are traditionally administered. Standard CAR T treatment is typically reserved for patients with relapsed or refractory disease characterized by measurable tumor burden on imaging and biopsy. In those settings, toxicities such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are common and are thought to be driven, at least in part, by robust CAR T-cell expansion in response to active disease.

By contrast, patients enrolled in ALPHA3 had achieved PET-negative or observation-appropriate responses after chemoimmunotherapy but were identified as high risk for relapse through positive circulating tumor DNA-based MRD testing. Despite receiving CAR T-cell therapy, none of the 12 patients treated with cema-cel experienced CRS or ICANS, a finding that Sharman described as notably different from expectations in the relapsed disease setting.

Beyond the absence of these hallmark CAR T-related toxicities, adverse events were generally manageable and consistent with those expected in patients recently completing chemoimmunotherapy. Some infections were reported, but overall treatment was well tolerated. Most patients received therapy in the outpatient setting, and the limited hospitalizations that occurred were considered unrelated to treatment.

Although the analysis remains preliminary and involves a small patient cohort, the findings provide encouraging evidence that CAR T-cell therapy administered in a minimal disease setting may offer a more favorable safety profile while maintaining the potential to eradicate residual disease.

Read the full interview here.